Logo
ON-DEMAND WEBINAR

The Present and Future of Lung Cancer Screening

This webinar reviews current evidence-based recommendations for the diagnosis and management of lung cancer screening and aims to provide a global perspective on eligibility criteria.

This on-demand webinar highlights:

  • Lung cancer screening in the US: Guidance and strategies to accelerating screening uptake

  • Implementation of lung cancer screening in the UK: Holistic approach on multiple layers

  • Current status of lung cancer screening and AI utilization in China: The role of AI nodule detection and characterization

Speakers
Ella Kazerooni

Professor Ella Kazerooni

Professor of Radiology and Internal Medicine at the University of Michigan Medical School, specializing in cardiothoracic radiology.

Currently serves as Chair of the ACR National Radiology Data Registry. She led the development of the first LungRADS schema for the interpretation and management of lung cancer screening CTs.

Philip Crosbie

Professor Philip Crosbie

Professor of Respiratory Medicine at the University of Manchester and Honorary Consultant at Wythenshawe Hospital, Manchester University NHS Foundation Trust.

He is a member of England's national expert advisory group for lung cancer screening, the Early Detection lead for the Cancer Research UK Lung Cancer Centre of Excellence.

Xueqian Xie

Professor Xueqian Xie 
MD, PhD, Deputy Director of Radiology Department at Shanghai General Hospital, Shanghai Jiaotong University School of Medicine.

He has undertaken > 10 chest imaging research projects and published more than 70 peer-reviewed papers including as corresponding author in Radiology, European Radiology, and JAMA Network Open.

  • Complete this form now to access the webinar

© 2024 Bayer

The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

BAYER, the Bayer Cross and Calantic are trademarks owned by Bayer and/or registered in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners.

This is intended to provide information for healthcare professionals and other relevant decision makers in the US, European Union, United Kingdom and Switzerland. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

The product Calantic Viewer has CE marking (CE2797). Complies with medical device legislation. Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information. The operating instructions of the product Calantic Viewer can be found on https://www.radiology.bayer.com/manuals

You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

PP-CALA-ALL-0764-1 January 2024